Illumina, Inc.

NASDAQ:ILMN

Medical - Diagnostics & Research

Healthcare
$210.01 +1.23%

+$1.95 today

Market cap
$31.75B
Beta
1.49
P/E (TTM)
28.9
EPS (TTM)
$5.58
52W Low $88.00High $177.22

Volume 1.63M

Average 1.65M

ILMN Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Illumina, Inc.NASDAQ: ILMN

Financing Cash Flow · Q2 FY2026 · quarter ended Jun 2026

Financing cash flow declines year over year

Q2 FY2026 financing cash flow of $129M (cash outflow) fell 65.2% year over year, behind the -41.0% change in trailing-twelve-month financing cash flow. Sequentially, it fell 48.6% from the prior quarter.

Context

  • Financing cash flow amounted to 17.2% of revenue in FY2025, up 4.1 pp from a year earlier.
  • Financing cash flow increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -65.2% toward the trailing-twelve-month pace of -41.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$129M-48.6% QoQ
Last fiscal yearDec 2025
-$744M+30.5% YoY
LTMJun 2026
-$558M-41.0% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-65.2%——
1 year+30.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
(744M) USD
Year-over-year change
-30.5%

Financing Cash Flow vs competitors

How ILMN compares with its peers on the latest reported figures

  • ILMN's LTM Jun 2026 financing cash flow of $558M is the 2nd largest of the 11 companies compared; the peer median is $48.95M.
  • Its year-over-year change of -41.0% is the 8th highest of 10, against a peer median of +94.9%.
  • Financing cash flow amounts to 12.4% of revenue for ILMN, versus a peer median of 11.0%.
ILMN Competitors Peer median
Financing Cash Flow for ILMN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GHGuardant Health, Inc.LTM Sep 2026$748.48M +1272.6%—58.5%
ILMNIllumina, Inc.LTM Jun 2026$558M -41.0%—12.4%
BLLNBillionToOne, Inc.LTM Jun 2026$326.54M ——82.2%
PSNLPersonalis, Inc.LTM Mar 2026$128.08M -4.2%+357.0%198.5%
WGSGeneDx Holdings Corp.LTM Jun 2026$73.56M +24.6%-37.6%16.2%
NTRANatera, Inc.LTM Jun 2026$50.31M +94.9%-53.8%1.9%
MYGNMyriad Genetics, Inc.LTM Mar 2026$47.6M +217.3%—5.7%
SOPHSOPHiA GENETICS S.A.LTM Mar 2026$46.34M +308.7%—57.1%
NEONeoGenomics, Inc.LTM Jun 2026$11.39M -94.3%—1.5%
PACBPacific Biosciences of California, Inc.LTM Mar 2026$2.91M +106.1%-29.1%1.8%
TXG10x Genomics, Inc.LTM Jun 2026$2.54M -129.5%-24.5%0.4%
Peer median (excluding ILMN) $48.95M+94.9%-29.1%11.0%

Competitors are the stored peer set for ILMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Jan 2022
FY2022
Jan 2023
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income762M(4.4B)(1.16B)(1.22B)850M
Depreciation & Amortization251M394M432M354M270M
Deferred Income Tax(76M)(23M)(33M)(112M)119M
Stock-Based Compensation754M366M380M370M275M
Change in Working Capital(152M)204M(90M)(483M)(153M)
Accounts Receivables(164M)(12M)(40M)(25M)(108M)
Inventory(58M)(135M)(20M)19M(17M)
Accounts Payables60M(38M)(44M)(4M)2M
Other Working Capital10M389M14M(473M)(30M)
Other Non-Cash Items(994M)3.86B950M1.93B(282M)
Operating Cash Flow545M392M478M837M1.08B
Capital Expenditures(208M)(286M)(195M)(128M)(148M)
Acquisitions (Net)(2.44B)(265M)(29M)2M(10M)
Purchases of Investments(77M)(40M)(6M)(52M)0
Sales of Investments1.66B0000
Other Investing Activities00(1M)0103M
Investing Cash Flow(1.07B)(591M)(231M)(178M)(55M)
Debt Repayment471M991M(1.24B)491M(5M)
Common Stock Issued60M63M67M56M44M
Common Stock Repurchased000(116M)(742M)
Dividends Paid00000
Other Financing Activities(582M)(54M)(42M)(1B)(41M)
Financing Cash Flow(51M)1B(1.21B)(570M)(744M)
Effect of Forex Changes(3M)(22M)0(10M)11M
Net Change in Cash(578M)779M(963M)79M291M
Free Cash Flow337M106M282M709M931M

Illumina, Inc.

NASDAQ:ILMN

Intrinsic Alpha fair value

Locked

Current Price

$210.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.